IP Library Granted Patent US 12,180,486
Granted Patent B2
US 12,180,486 · App. 16/711,011 · Granted Dec 31, 2024

Compositions of self-reporting transposon (SRT) constructs and methods for mapping transposon insertions

Inventors: Robi D. Mitra (St. Louis, MO); Arnav Moudgil (St. Louis, MO); Michael Nathaniel Wilkinson (St. Louis, MO); Zongtai Qi (St. Louis, MO)
Assignee: Washington University
C12N15/635C12N9/22C12N15/102C12N15/113C12N15/907C12N2310/11C12N2310/20C12N2310/3513
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,180,486
App. No.
16/711,011
Granted
Dec 31, 2024
Kind
B2
Abstract

Among the various aspects of the present disclosure is the provision of compositions and methods for mapping transposon insertions. Applications can include mapping the locations of self-reporting transposons (SRTs) from thousands of single cells in parallel, while simultaneously measuring mRNA abundance from the same single cells; analyzing genome-associated protein (GAP) (e.g., transcription factor) binding/interactions in a small number of cells in bulk, without single cell resolution; lineage tracing; or as an improved readout for transposon mutagenesis screens.

Claims (12)

1. A self-reporting transposon (SRT) construct comprised of a transposon containing transposon DNA and at least one promoter; wherein the promoter is capable of driving transcription of DNA through at least one transposon end after the SRT construct is inserted into genomic DNA so that a portion of the transposon DNA, the at least one transposon end, and genomic DNA flanking the transposon end is transcribed into RNA; and wherein the transposon does not contain a poly-adenylation (poly-A) termination signal in the transcribed region.

2. The SRT construct of claim 1 , wherein the promoter is an inducible promoter.

3. The SRT construct of claim 2 , wherein the inducible promoter is capable of being induced by a chemical inducer and light.

4. The SRT construct of claim 1 , wherein the promoter comprises an EF1α promoter, a CAG promoter, a PGK promoter, a Tet-on or Tet-off promoter, a T7 promoter, or a CMV promoter.

5. The SRT construct of claim 1 , wherein the promoter drives expression of a reporter gene incorporated in the transposon.

6. The SRT construct of claim 5 , wherein the reporter gene is selected from the group consisting of:

a gene encoding a fluorescent protein;

a gene capable of use as a selectable marker by conferring resistance to a chemical agent that kills eukaryotic or prokaryotic cells; and

a gene encoding an enzyme capable of converting a chemical substrate into a colorimetric reporter, a luminescent reporter, or a fluorescent reporter.

7. The SRT construct of claim 6 , wherein the gene encoding a fluorescent protein comprises green fluorescent protein, tdTomato, eGFP, or eCFP.

8. The SRT construct of claim 6 , wherein the gene capable of use as a selectable marker comprises puromycin N-acetyl-transferase, an aminoglycoside 3′ phosphotransferase gene encoded by Tn5 and Tn601, or hygromycin phosphotransferase.

9. The SRT construct of claim 1 , wherein the transposon encodes a Woodchuck Hepatitis Virus (WHP) Posttranscriptional Regulatory Element (WPRE).

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 2, 2022
From: WASHINGTON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061054/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2020
From: MITRA, ROBI D.; MOUDGIL, ARNAV; WILKINSON, MICHAEL NATHANIEL; QI, ZONGTAI
To: WASHINGTON UNIVERSITY
Reel/Frame 051397/0206 →
Continuity (2)
Provisional Application 62777995 · Dec 11, 2018
Related Publication 20200181626A1 · Jun 11, 2020